CapitalBio Corporation to Offer Genotyping Services Using Affymetrix 500K Array in China; Company Earns Affymetrix Service Provider Certification.SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. , Calif. & BEIJING -- Affymetrix Inc., (Nasdaq:AFFX) and CapitalBio Corporation, a leading life science company based in Beijing, P.R. China, announced today that CapitalBio has become a certified Affymetrix Service Provider and will begin offering genotyping Genotyping refers to the process of determining the genotype of an individual with a biological assay. Current methods of doing this include PCR, DNA sequencing, and hybridization to DNA microarrays or beads. services using the Affymetrix GeneChip(R) Human Mapping 500K Array Set. The 500K Array enables researchers to search across the entire genome in detail to find genes involved in disease or drug response. CapitalBio has been offering gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, services using Affymetrix microarray technology for more than a year. The two companies have also been working together on joint R&D and commercialization programs, including the development of an advanced GeneChip-compatible personal scanner. "The gene expression and genotyping market are gaining momentum as more and more international pharmaceutical companies out-source microarray services in China and more and more Chinese scientists employ microarrays to solve biological problems," said David Sun, senior vice president, Business Development and Marketing at CapitalBio. "As a Certified Affymetrix Service Provider, CapitalBio can now provide broader high quality microarray based services beyond its already extensive products and services to gain information at gene, protein, cell and tissue levels to address the increasing needs of global customers." "CapitalBio has been offering microarray services using Affymetrix technology for more than a year and has demonstrated its ability to provide quality services using 500K arrays," said Wei Zhou, vice president and country manager of China at Affymetrix. "Affymetrix is committed to enabling the Chinese scientific community to access to all of the statistical power in the Affymetrix genotyping arrays to gain a better understanding of the genetic causes of complex disease." About CapitalBio CapitalBio is a leading life science Company that develops and commercializes a broad range of products, including Biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of technology products, for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive life science entity with five affiliates or subsidiaries: AVIVA Biosciences, a San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a Biotech company located in Shenzhen, China, for small molecular drug discovery and development; and CapitalBio International and CapitalBio Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. , two fully owned subsidiaries by CapitalBio Corporation, are based at San Diego, California and Hong Kong, China respectively. Additional information on CapitalBio can be found at www.capitalbio.com. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic pho·to·li·thog·ra·phy n. A planographic printing process using plates made according to a photographic image. pho manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the genotyping services that CapitalBio will offer, risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. ; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other risk factors are discussed in Affymetrix' Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc. CapitalBio, and the CapitalBio logo, and Capital Biochip are registered trademarks owned or used by CapitalBio Corporation. AVIVA, Chipscreen are registered trademarks owned or used by AVIVA Biosciences and Chipscreen Biosciences respectively. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion